Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

entecavir

- PMLiVE

Teva’s migraine injection approved in Europe

Third anti-CGRP treatment to hit the market

Bristol Myers Squibb logo

BMS closes on Celgene merger after rebel investors bow out

News on Revlimid patent also positive

Bristol Myers Squibb logo

BMS defends Celgene buyout ahead of shareholder vote

BMS battles for hearts and minds before shareholder vote

Bristol-Myers Squibb (BMS) building

BMS trades blows with investor on Celgene deal merits

Activist investors claim Celgene’s pipeline is “extremely risky”

Bristol-Myers Squibb (BMS) building

Reluctant shareholders threaten $74bn BMS merger with Celgene

Shareholders claim merger undervalues BMS but analysts convinced the deal will close

Celgene building

FDA begins speedy review of Celgene’s Revlimid combo in lymphoma

R2 met its primary endpoint of PFS in trials

- PMLiVE

Teva will have to endure revenue ‘trough’ in 2019

Company looks to migrane treatment Ajovy for growth

- PMLiVE

Industry aghast as EU Parliament backs biosimilar rule change

The change could come into effect in 2021

Bristol Myers Squibb logo

BMS isn’t phased by Opdivo’s slowing growth – for now

Lung cancer filing withdrawn after FDA reservations

- PMLiVE

Chinese biotechs aim PD-L1 antibody at hepatitis B

Cancer therapies could help boost patient's immune system

- PMLiVE

Nektar confirms BMS deal for NKTR-214 is on track

Shares in Nektar rose 10% in the wake of the presentation at JPM healthcare conference

- PMLiVE

BMS and Celgene deal sparks debate on pharma profit motive, more M&A

Biopharma backlash at Warren tweet, but Celgene tactics in the spotlight

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links